INTRODUCTION
Diffuse neonatal hemangiomatosis (DNH) is a rare and fatal disorder characterized by multiple cutaneous and visceral hemangiomas at birth or during the neonatal period 1) .
The areas most commonly involved with visceral hemangiomas are the liver (64100%), central nervous system (52%), respiratory tract, and gastrointestinal tract 2) . The condition is lifethreatening with a mortality rate of 6085% without appropriate treatment. Causes of death include highoutput heart failure caused by a highflow hepatic hemangioma with a large shunt, extensive bleeding of a hemangioma, hepatic failure, or disseminated intravascular coagulopathy in which platelets and clotting factors are activated within the hemangiomas 2) . Corticosteroids are the first drug of choice; however, the response rate is just 3060% 3) . There have been numerous case reports of DNH treated with interferonalpha, vincristine, cyclophosphamide, or propranolol as a secondline treatment when patients were refractory to firstline corticosteroid treatment 1, 35) . However, the response rates, adverse effects, dosages, and durations of second line treatments for DNH are not yet clearly defined owing to a lack of prospective, randomized, controlled studies. We present here a case of a newborn baby with multiple hemangiomas in her skin (including the scalp, lips, neck, back, shoulder, arm, buttock, and leg), brain (right cerebellum, pons, and medulla oblongata), lungs, liver, and kidney. We initiated treatment with oral prednisolone (4 mg/kg/ day) from the 27 th through the 55 th postnatal days for a total duration of 4 weeks; however, no clinical response was observed.
Therefore, oral propranolol (2 mg/kg/day) was administered as a secondline treatment and no significant adverse effects; such as hypoglycemia, bradycardia, hypotension, and so for . A treatment with a corticosteroid was effective in just one Korean case 7) , and the remaining five were found to be refractory to the usual corticosteroids 8) . In those cases, the hemangiomas improved by treatment with prednisolone con comitant with interferonalpha, vincristine, or highdose methylprednisolone pulse therapy. ; however, in some intensive care units, it is used as a firstline treatment. In one prospective study, 31 newborn patients with infantile hemangioma were treated with 3 mg/kg/day of propranolol as an initial treatment and this was shown to be effective without significant adverse effects 18) . The rapid proliferation of the hemangiomas ceased and then regressed in all patients. The response to propranolol is more rapid than that to corticosteroids, usually 14 days; how ever, some studies have reported a response up to 8 months after treatment 18) . Propranolol downregulates angiogenetic growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) by blocking beta adrenoceptors 19, 20) . It also induces vasoconstriction by decreasing nitric oxide and enhances apoptosis of endothelial cells, result ing in the regression of hemangiomas. Adverse effects such as bradycardia, hypotension, bronchospasm, and hypoglycemia can occur. While this is very rare in newborn or young infants, cardiovascular checks such as pulse rate, blood pressure, elec trocardiograms, and echocardiograms are needed prior to the initiation of propranolol treatment 5, 19) .
The adequate dosage and optimal duration of propranolol administration in neonates are not yet clearly defined and re main uncertain due to a lack of prospective, randomized, con trolled studies. Sufficiently long treatment periods are required to prevent rebound growth of hemangiomas in vital organs.
Thus, the recommended duration of propranolol treatment is approximately 7 months as DNH may continue to proliferate for a period of time after birth and after proapoptotic components become predominant 19) .
In conclusion, we present here a case of a patient with DNH with cranial nerve palsy refractory to a corticosteroid in whom propranolol was effective without significant adverse effects.
Propranolol can be considered as a firstline rescue treatment in lifethreatening cases of DNH. Additional prospective, ran domized, controlled studies comparing secondline drugs with corticosteroids are required, although the implementation of such studies will be difficult, owing to the rarity of this condition. . Furthermore, the occurrence of rebound growth of he mangiomas after cessation of corticosteroids is as high as 36% 12) .
As a result, newer secondline treatments that are both more effective and welltolerated over longterm use are needed.
There have been numerous studies investigating the use of interferonalpha, vincristine, cyclophosphamide, and propra nolol as se condline treatments for DNH patients re fractory to corticoste roid treatment. Interferonalpha was shown to be effective in treating neonatal hemangioma complicated with consumptive coagulopathy refractory to corticosteroids by inhibiting the proliferation of endothelial cells and angio genesis 14) . The ad verse effects of interferonalpha include neu tropenia, anemia, neurotoxicity, elevated liver enzyme levels, and thyroid dys function 3, 14, 15) . Vincristine, a cancer che mo therapy agent, was also shown to be effective in treating DNH refractory to cor ticosteroids by inhibiting cell mitosis in the metaphase, interfering with tubulin polymerization, and pro voking cellular apoptosis 4, 16) . The adverse effects of vincristine include neurotoxicity, spastic diplegia, and hair loss 4, 16) . Cyclo phosphamide has been used as a rescue treatment for life threatening DNH 1) . While it was shown to be effective, it can cause hemorrhagic cystitis, cardiomyopathy, pulmonary fibrosis, and secondary malignancy 1, 17) .
Propranolol, a nonselective betaadrenergic blocker (class 2 antiarrhythmic), is commonly used for the treatment of hyper tension or arrhythmia. It is generally used as a secondline treat 
